Varicella-zoster virus-specific antibody responses in 50-59-year-old recipients of zoster vaccine.
rct · Level II
Where this comes from
- Record sourced from PubMed, PMID 23908486.
- Also identified by DOI 10.1093/infdis/jit342 and PMC identifier 4550114.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Prevaccination and 6-week postvaccination samples from the immunogenicity substudy (n = 2269) of the zoster vaccine (ZV) efficacy trial (N = 22 439) in 50-59-year-old subjects were examined for varicella-zoster virus-specific antibody responses to vaccination. The varicella-zoster virus geometric mean titer (GMT) and geometric mean fold rise were higher in ZV recipients than in placebo recipients (GMT, 660.0 vs 293.1 glycoprotein enzyme-linked immunosorbent assay units/mL [P < .001], respectively; geometric mean fold rise, 2.31 vs 1.00 [P < .025]). In each group there was a strong inverse correlation between postvaccination GMT and risk of subsequent herpes zoster. Although these data provide strong evidence that relates ZV-induced antibody and the risk of herpes zoster, a protective threshold was not determined. Clinical Trials Registration. NCT00534248.
Medical subject headings
- Antibodies, Viral
- Herpes Zoster
- Herpes Zoster Vaccine
- Herpesvirus 3, Human